Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):e59-63. doi: 10.1016/j.clml.2013.11.007. Epub 2013 Nov 15.

Authors

Ajay K Nooka¹, R Donald Harvey², Amelia Langston², Hannah Collins², Sagar Lonial², Jonathan L Kaufman²

Affiliations

¹ Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA. Electronic address: [email protected].
² Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.

PMID: 24378319
DOI: 10.1016/j.clml.2013.11.007

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Agents, Alkylating / therapeutic use
Creatine / blood
Dose-Response Relationship, Drug
Female
Glomerular Filtration Rate
Hematopoietic Stem Cell Transplantation / methods*
Humans
Male
Melphalan / therapeutic use*
Middle Aged
Multiple Myeloma / complications
Multiple Myeloma / therapy*
Renal Insufficiency / complications
Renal Insufficiency / physiopathology*
Transplantation Conditioning / methods*
Transplantation, Autologous
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Creatine
Melphalan